Berchuck A - Search Results

1

Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.

Lurie G, Wilkens LR, Thompson PJ, Shvetsov YB, Matsuno RK, Carney ME, Palmieri RT, Wu AH, Pike MC, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Ramus SJ, Whittemore AS, McGuire V, Sieh W, Pharoah PD, Song H, Gronwald J, Jakubowska A, Cybulski C, Lubinski J, Schildkraut JM, Berchuck A, Krüger Kjær S, Høgdall E, Fasching PA, Beckmann MW, Ekici AB, Hein A, Chenevix-Trench G, Webb PM, Beesley J; Australian Ovarian Cancer Study Group; Australian Cancer Study Group; Goodman MT; Ovarian Cancer Association Consortium. Lurie G, et al. Among authors: berchuck a. PLoS One. 2011;6(6):e20703. doi: 10.1371/journal.pone.0020703. Epub 2011 Jun 6. PLoS One. 2011. PMID: 21673961 Free PMC article.

2

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Schildkraut JM, et al. Among authors: berchuck a. Am J Obstet Gynecol. 1995 Mar;172(3):908-13. doi: 10.1016/0002-9378(95)90020-9. Am J Obstet Gynecol. 1995. PMID: 7892884

3

An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.

Lancaster JM, Wiseman RW, Berchuck A. Lancaster JM, et al. Among authors: berchuck a. Obstet Gynecol. 1996 Feb;87(2):306-9. doi: 10.1016/0029-7844(95)00405-X. Obstet Gynecol. 1996. PMID: 8559544

4

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

5

Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.

Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Lancaster JM, et al. Among authors: berchuck a. Mol Carcinog. 1996 Nov;17(3):160-2. doi: 10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J. Mol Carcinog. 1996. PMID: 8944076

6

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

Schildkraut JM, Bastos E, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. J Natl Cancer Inst. 1997 Jul 2;89(13):932-8. doi: 10.1093/jnci/89.13.932. J Natl Cancer Inst. 1997. PMID: 9214672

7

Dideoxy fingerprinting assay for BRCA1 mutation analysis.

Lancaster JM, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. Among authors: berchuck a. Mol Carcinog. 1997 Jul;19(3):176-9. Mol Carcinog. 1997. PMID: 9254884

8

Human ovarian cancer of the surface epithelium.

Berchuck A, Carney M. Berchuck A, et al. Biochem Pharmacol. 1997 Sep 1;54(5):541-4. doi: 10.1016/s0006-2952(97)00061-0. Biochem Pharmacol. 1997. PMID: 9337069 Review.

9

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

10

Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.

Berchuck A, Carney M, Lancaster JM, Marks J, Futreal AP. Berchuck A, et al. Clin Obstet Gynecol. 1998 Mar;41(1):157-66. doi: 10.1097/00003081-199803000-00022. Clin Obstet Gynecol. 1998. PMID: 9504233 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

640 results

Search Page

Filters